YFM Group and Swarraton Partners have led a £2m (€2.5m) investment in Micrima, which is developing radio wave technology to improve detection of breast cancer. Existing investor the National Endowment of Science, Technology and the Arts also participated in the funding. University of Bristol spin-out Micrima, led by executive chairman Roy Johnson (pictured), is developing a breast imaging system that captures high resolution, 3D images through the use of harmless radio waves. Its MARIA (multistatic array processing for radiowave image acquisition) system can provide better images for the dense tissue associated with the under 50s age group, and is also relatively inexpensive and completely safe for the patient. The product’s low cost and compact size allow for its practical use in numerous alternative locations such as GP surgeries, diagnostic centres and mobile screening units. Funding will go toward ongoing technical development and further clinical trials at the Frenchay Hospital’s Breast Clinic in Bristol.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.